2025 CPT code 81273
Effective Date: N/A Pathology and Laboratory Procedures - Molecular Pathology Procedures Feed
KIT (v-kit Hardy-Zuckerman 4 feline sarcoma viral oncogene homolog) (eg, mastocytosis), gene analysis, D816 variant(s).
Modifier 26 can be appended to 81273 if only the professional component (interpretation and report) is performed. Modifier 59 may be used to indicate that this is a distinct procedural service.
Medical necessity for this test depends on clinical suspicion for a condition associated with KIT gene variants, especially systemic mastocytosis or certain types of leukemia. The test must be ordered by a physician and performed in a CLIA-certified laboratory. Payer guidelines for coverage may vary.
The laboratory analyst performs the technical aspects of the test, including nucleic acid extraction, amplification, and detection. The interpretation of results is typically done by a physician or other qualified healthcare professional (which may be reported separately using modifier 26 and code G0452).
In simple words: This test analyzes a specific gene called KIT for changes (variants), particularly one called D816. The KIT gene is responsible for making proteins that control how cells grow and survive. This test helps diagnose and manage certain diseases, like systemic mastocytosis (a type of blood cancer) and some leukemias, where these proteins aren't working correctly.
This code describes a molecular pathology procedure involving the analysis of the KIT gene for the presence of the D816 variant(s). The KIT gene codes for receptor tyrosine kinases which influence cell growth, division, and survival. This test is often used to aid in the diagnosis and treatment guidance of systemic mastocytosis (SM) and certain leukemias.
Example 1: A patient presents with symptoms suggestive of systemic mastocytosis. The physician orders a KIT D816 variant analysis (81273) to confirm the diagnosis., A patient with acute myeloid leukemia undergoes genetic testing. The 81273 code is used to assess for the presence of KIT D816 mutations, which can influence treatment decisions and prognosis., A patient diagnosed with systemic mastocytosis is being considered for treatment with a tyrosine kinase inhibitor. The 81273 test is used to determine if the patient's specific KIT D816 variant is sensitive to the medication.
Documentation should include the reason for the test (e.g., signs and symptoms suggestive of mastocytosis or leukemia), relevant medical history, and informed consent (if applicable). Pathology report should include the test methodology and interpretation of the results.
- Specialties:Hematology/Oncology, Pathology, and sometimes Dermatology or Allergy/Immunology
- Place of Service:Independent Laboratory, On Campus-Outpatient Hospital, and Off Campus-Outpatient Hospital.